CN105641674A - Compound nanometer preparation for treating diabetes mellitus type 2 and preparation method thereof - Google Patents

Compound nanometer preparation for treating diabetes mellitus type 2 and preparation method thereof Download PDF

Info

Publication number
CN105641674A
CN105641674A CN201610051589.7A CN201610051589A CN105641674A CN 105641674 A CN105641674 A CN 105641674A CN 201610051589 A CN201610051589 A CN 201610051589A CN 105641674 A CN105641674 A CN 105641674A
Authority
CN
China
Prior art keywords
diabetes mellitus
preparation
parts
compound recipe
excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610051589.7A
Other languages
Chinese (zh)
Inventor
李华红
韩晓丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610051589.7A priority Critical patent/CN105641674A/en
Publication of CN105641674A publication Critical patent/CN105641674A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses a compound nanometer preparation for treating the diabetes mellitus type 2 and a preparation method thereof. The compound nanometer preparation for treating the diabetes mellitus type 2 is mainly prepared from, by weight, 8-15 parts of aloe acetylation gulcomannan, 3-6 parts of Cicletanine, 1-2 parts of decanoyl acetaldehyde, 4-8 parts of syringaresinol monoglucoside, 5-20 parts of banana leaf powder, 3-7 parts of grapefruit seed extract, 1-4 parts of sodium ethylene diamine tetracetate, 0.8-2.0 parts of myristic acid, 0.1-0.5 part of syringic acid, 0.1-0.3 part of gentisic acid, 3-10 parts of lysine, 1-3 parts of carotenoid and 0.03-0.1 part of antioxidant. According to the compound nanometer preparation, blood glucose rising is controlled through interaction of various ingredients, the blood pressure and blood fat of a patient suffering from the diabetes mellitus type 2 are adjusted, sufficient nutritional ingredients can be provided for the patient suffering from the diabetes mellitus type 2, the immunity of the patient is improved, diabetes mellitus and arteriosclerosis are relieved, the effect of treating the diabetes mellitus type 2 is remarkable, and the side effect is small.

Description

A kind of compound recipe nanometer formulation treating type 2 diabetes mellitus and preparation method thereof
Technical field
The present invention relates to the drug world relevant to diabetes, be specifically related to a kind of compound recipe nanometer formulation treating type 2 diabetes mellitus and preparation method thereof.
Background technology
Diabetes are the lysis caused by multi-pathogenesis, have influence on the population of whole world 6%-7%, it is contemplated that by 2025, number of patients can be further added by one times and reach 300,000,000. The principal character of diabetes is exactly hyperglycemia, and hyperglycemia is owing to defect of insulin secretion or its biological agent are impaired, or both have concurrently and cause. Long-standing hyperglycemia during diabetes, causes various tissue, particularly eye, kidney, heart, blood vessel, neural chronic lesion, dysfunction.
Type 2 diabetes mellitus is common in middle-aged and elderly people, and overweight people's sickness rate is high, often can with hypertension, the disease such as dyslipidemia, arteriosclerosis. Insidious onset, early stage is without any symptom, or only has slightly weak, thirsty, and blood glucose increases inconspicuous person need to be done carbohydrate tolerance test and just can make a definite diagnosis. Serum insulin levels early stage is normal or increases, and late period is low.
In recent years, it is widely used in treatment type 2 diabetes mellitus as sulfonylurea, the such conventional medicine of biguanides, but therapeutic effect is not often complied with one's wishes. In many experimenters, this kind of medicine can not make blood glucose (BG) level normalization to expected degree, and this makes patient have more excessive risk that further diabetic complication occurs. And these medicines cause side effect in many patients. Such as, when being used alone or be used in combination with other drug, sulfonylurea can bring out hypoglycemia, and metformin can cause gastrointestinal upset, and the incidence rate of this side effect can increase with the raising of dosage. Life-time service metformin can also cause homocysteine levels to improve, it is possible to causes the malabsorption of vitamin B12, it is also possible to induction produces lactic acid, causes the lactic acidosis of some PATIENT POPULATION.
Another Therapeutic Method uses trypsin class medicine exactly. Generally, by changing lifestyles and using oral antidiabetic drug still can not control blood glucose well, or taking other drug when can bring harmful effect to you, doctor's possibility will advise using insulin.At present, insulin can not be administered orally, and passes through subcutaneous injection only with syringe or insulin pen device. Onset time and the acting duration of different insulin preparations are also different. Needs of patients, under the guidance of doctor, is selected the insulin-type being suitable for self current state of an illness, and is formulated the suitable injection of insulin time.
Therefore, research and develop Drug therapy type 2 diabetes mellitus novel, that side effect is little to have and important clinical meaning.
Summary of the invention
Present invention solves the technical problem that and be to provide a kind of compound recipe nanometer formulation treating type 2 diabetes mellitus and preparation method thereof, treatment type 2 diabetes mellitus effect is notable and non-evident effect.
For solving technique scheme; the technical solution adopted in the present invention is: a kind of compound recipe nanometer formulation treating type 2 diabetes mellitus, is mainly grouped into by the one-tenth of following weight portion: aloe acetylated glucomannoglycan 8-15 part, cicletanine 3-6 part, decanoylacetaldehyde 1-2 part, syringaresinol monoglycosides 4-8 part, Banana Leaf powder 5-20 part, grapefruit seed extract 3-7 part, sodium ethylene diamine tetracetate 1-4 part, myristic acid 0.8-2.0 part, syringic acid 0.1-0.5 part, gentisic acid 0.1-0.3 part, lysine 3-10 part, carotenoid 1-3 part, antioxidant 0.03-0.1 part.
Further, the particle diameter of described Banana Leaf powder is 100-500 ��m, the preparation technology of described Banana Leaf powder is: takes fresh Banana Leaf and cleans, it is placed in immersion treatment 30-60min in 0.5-1.2% sodium bicarbonate solution, pulls out, dry, it is placed in dehydrator inner drying to water content lower than 5%, it is ground into the coarse powder of 40 orders with pulverizer, is crushed to the micropowder of 100-500 ��m then through super micron mill, namely obtain described Banana Leaf powder.
Further, described grapefruit seed extract is purchased from Xi'an Si Nuote Bioisystech Co., Ltd, and grapefruit seed extract can completely cut off the absorption of fat, postpones the absorption of glucose, reduces body fat, reduces the cholesterol in blood and raises with alleviating blood glucose.
Further, described antioxidant is glutathion, and glutathion possesses anticorrosion, antioxidation, also has the effects such as wide spectrum removing toxic substances, slow down aging, enhancing immunity, antitumor.
The preparation method of a kind of compound recipe nanometer formulation treating type 2 diabetes mellitus, comprises the following steps:
(1) aloe acetylated glucomannoglycan, cicletanine, decanoylacetaldehyde, syringaresinol glucosides, Banana Leaf powder, grapefruit seed extract, sodium ethylene diamine tetracetate, myristic acid, syringic acid, gentisic acid, lysine, carotenoid, antioxidant are weighed by described components by weight percent, standby;
(2) all the components mix homogeneously in mixer above-mentioned steps (1) weighed, adds the adhesive of the filler of 5-20%, 8-15%, mixing, makes particle diameter fine grained in 200-500 micrometer range, standby;
(3) the fine grained surface obtained by step (2) is mixed pharmaceutically acceptable excipient carry out three layers cladding with protein, polysaccharide, nanoparticle respectively, wherein, ground floor is to be coated with excipient mixture with the protein relative to fine particle mass 0.5-1.3 times amount, and the part by weight of protein and excipient is 1:8-10; The second layer is to be coated with excipient mixture with the polysaccharide relative to fine particle mass 1.5-2.8 times amount, and the part by weight of polysaccharide and excipient is 1:6-10; Third layer is to be coated with excipient mixture with the nanoparticle relative to fine particle mass 4.2-5.0 times amount, and the part by weight of nanoparticle and excipient is 1:5-10.
Further, described excipient is soluble starch, and soluble starch stable in properties with principal agent without incompatibility, does not have side effects, do not affect the treatment.
Further, described protein is soybean protein or trichosanthin, it is possible to provides sufficient nutritional labeling for diabetics, improves body's immunity.
Further, described polysaccharide is lentinan or Flammukinan, it is possible to improves body immunity, moreover it is possible to blood sugar lowering, blood fat, cholesterol, improves diabetes and arteriosclerosis.
Further, described nanoparticle is nano hydroxyapatite Calx, nano hydroxyapatite Calx has the advantages such as height targeting, drug controlled release, the dissolution rate of raising insoluble medicine and absorbance as nano-medicament carrier, can improve curative effect of medication and reduce toxic and side effects.
Further, described filler is microcrystalline Cellulose, and it does not play ill effect with drug component, and improves pharmaceutical properties.
Further, described adhesive is the alcoholic solution of ethyl cellulose, and in the alcoholic solution of described ethyl cellulose, the mass concentration of ethyl cellulose is 2-10%, it is simple to granulate.
The invention has the beneficial effects as follows: cooperating by Multiple components, control blood glucose and raise, and regulate the blood pressure of type 2 diabetes mellitus patient, blood fat; Wherein, grapefruit seed extract can completely cut off the absorption of fat, postpones the absorption of glucose, reduces body fat, reduces the cholesterol in blood and raises with alleviating blood glucose; Aloe acetylated glucomannoglycan, syringaresinol monoglycosides, Banana Leaf powder, sodium ethylene diamine tetracetate, myristic acid etc. can control blood glucose and raise; Cicletanine can regulate blood pressure; Decanoylacetaldehyde, syringic acid, gentisic acid share can antioxidation, leukocytes phagocytic ability and improve serum for interleukin in reinforcement, transfer immunity of organisms; Lysine, carotenoid and protein, polysaccharide can provide sufficient nutritional labeling for diabetics, improve patient's immunity, moreover it is possible to blood sugar lowering, blood fat, cholesterol, improve diabetes and arteriosclerosis; Drug therapy type 2 diabetes mellitus effect of the present invention is notable, and side effect is only small.
Detailed description of the invention
Embodiment 1:
A kind of compound recipe nanometer formulation treating type 2 diabetes mellitus, is mainly grouped into by the one-tenth of following weight portion: aloe acetylated glucomannoglycan 8 parts, cicletanine 3 parts, decanoylacetaldehyde 1 part, syringaresinol monoglycosides 4 parts, 5 parts of Banana Leaf powder, grapefruit seed extract 3 parts, sodium ethylene diamine tetracetate 1 part, myristic acid 0.8 part, syringic acid 0.1 part, gentisic acid 0.1 part, lysine 3 parts, carotenoid 1 part, antioxidant 0.03 part.
Wherein, the particle diameter of described Banana Leaf powder is 100 ��m, the preparation technology of described Banana Leaf powder is: takes fresh Banana Leaf and cleans, it is placed in immersion treatment 30min in 0.5% sodium bicarbonate solution, pulls out, dry, it is placed in dehydrator inner drying to water content lower than 5%, it is ground into the coarse powder of 40 orders with pulverizer, is crushed to the micropowder of 100 ��m then through super micron mill, namely obtain described Banana Leaf powder. Described grapefruit seed extract is purchased from Xi'an Si Nuote Bioisystech Co., Ltd, and grapefruit seed extract can completely cut off the absorption of fat, postpones the absorption of glucose, reduces body fat, reduces the cholesterol in blood and raises with alleviating blood glucose. Described antioxidant is glutathion, and glutathion possesses anticorrosion, antioxidation, also has the effects such as wide spectrum removing toxic substances, slow down aging, enhancing immunity, antitumor.
The preparation method of a kind of compound recipe nanometer formulation treating type 2 diabetes mellitus, comprises the following steps:
(1) aloe acetylated glucomannoglycan, cicletanine, decanoylacetaldehyde, syringaresinol glucosides, Banana Leaf powder, grapefruit seed extract, sodium ethylene diamine tetracetate, myristic acid, syringic acid, gentisic acid, lysine, carotenoid, antioxidant are weighed by described components by weight percent, standby;
(2) all the components mix homogeneously in mixer above-mentioned steps (1) weighed, adds the filler of 5%, the adhesive of 8%, mixing, makes particle diameter fine grained in 200 micrometer ranges, standby; Described filler is microcrystalline Cellulose, and it does not play ill effect with drug component, and improves pharmaceutical properties. Described adhesive is the alcoholic solution of ethyl cellulose, and in the alcoholic solution of described ethyl cellulose, the mass concentration of ethyl cellulose is 2%, it is simple to granulate.
(3) the fine grained surface obtained by step (2) is mixed pharmaceutically acceptable excipient carry out three layers cladding with protein, polysaccharide, nanoparticle respectively, wherein, ground floor is to be coated with excipient mixture with the protein relative to fine particle mass 0.5 times amount, and the part by weight of protein and excipient is 1:8; The second layer is to be coated with excipient mixture with the polysaccharide relative to fine particle mass 1.5 times amount, and the part by weight of polysaccharide and excipient is 1:6; Third layer is to be coated with excipient mixture with the nanoparticle relative to fine particle mass 4.2 times amount, and the part by weight of nanoparticle and excipient is 1:5. Described excipient is soluble starch, and soluble starch stable in properties with principal agent without incompatibility, does not have side effects, do not affect the treatment. Described protein is soybean protein or trichosanthin, it is possible to provides sufficient nutritional labeling for diabetics, improves body's immunity. Described polysaccharide is lentinan or Flammukinan, it is possible to improves body immunity, moreover it is possible to blood sugar lowering, blood fat, cholesterol, improves diabetes and arteriosclerosis. Described nanoparticle is nano hydroxyapatite Calx, and nano hydroxyapatite Calx has the advantages such as height targeting, drug controlled release, the dissolution rate of raising insoluble medicine and absorbance as nano-medicament carrier, can improve curative effect of medication and reduce toxic and side effects.
Embodiment 2:
A kind of compound recipe nanometer formulation treating type 2 diabetes mellitus, is mainly grouped into by the one-tenth of following weight portion: aloe acetylated glucomannoglycan 11.5 parts, cicletanine 4.5 parts, decanoylacetaldehyde 1.5 parts, syringaresinol monoglycosides 6 parts, 12.5 parts of Banana Leaf powder, grapefruit seed extract 5 parts, sodium ethylene diamine tetracetate 2.5 parts, myristic acid 1.4 parts, syringic acid 0.3 part, gentisic acid 0.2 part, lysine 6.5 parts, carotenoid 2 parts, antioxidant 0.065 part.
Wherein, the particle diameter of described Banana Leaf powder is 300 ��m, the preparation technology of described Banana Leaf powder is: takes fresh Banana Leaf and cleans, it is placed in immersion treatment 45min in 0.85 sodium bicarbonate solution, pulls out, dry, it is placed in dehydrator inner drying to water content lower than 5%, it is ground into the coarse powder of 40 orders with pulverizer, is crushed to the micropowder of 300 ��m then through super micron mill, namely obtain described Banana Leaf powder. Described grapefruit seed extract is purchased from Xi'an Si Nuote Bioisystech Co., Ltd, and grapefruit seed extract can completely cut off the absorption of fat, postpones the absorption of glucose, reduces body fat, reduces the cholesterol in blood and raises with alleviating blood glucose.Described antioxidant is glutathion, and glutathion possesses anticorrosion, antioxidation, also has the effects such as wide spectrum removing toxic substances, slow down aging, enhancing immunity, antitumor.
The preparation method of a kind of compound recipe nanometer formulation treating type 2 diabetes mellitus, comprises the following steps:
(1) aloe acetylated glucomannoglycan, cicletanine, decanoylacetaldehyde, syringaresinol glucosides, Banana Leaf powder, grapefruit seed extract, sodium ethylene diamine tetracetate, myristic acid, syringic acid, gentisic acid, lysine, carotenoid, antioxidant are weighed by described components by weight percent, standby;
(2) all the components mix homogeneously in mixer above-mentioned steps (1) weighed, adds the filler of 12.5%, the adhesive of 11.5%, mixing, makes particle diameter fine grained in 350 micrometer ranges, standby; Described filler is microcrystalline Cellulose, and it does not play ill effect with drug component, and improves pharmaceutical properties. Described adhesive is the alcoholic solution of ethyl cellulose, and in the alcoholic solution of described ethyl cellulose, the mass concentration of ethyl cellulose is 6%, it is simple to granulate.
(3) the fine grained surface obtained by step (2) is mixed pharmaceutically acceptable excipient carry out three layers cladding with protein, polysaccharide, nanoparticle respectively, wherein, ground floor is to be coated with excipient mixture with the protein relative to fine particle mass 0.9 times amount, and the part by weight of protein and excipient is 1:9; The second layer is to be coated with excipient mixture with the polysaccharide relative to fine particle mass 2.15 times amount, and the part by weight of polysaccharide and excipient is 1:8; Third layer is to be coated with excipient mixture with the nanoparticle relative to fine particle mass 4.6 times amount, and the part by weight of nanoparticle and excipient is 1:7.5. Described excipient is soluble starch, and soluble starch stable in properties with principal agent without incompatibility, does not have side effects, do not affect the treatment. Described protein is soybean protein or trichosanthin, it is possible to provides sufficient nutritional labeling for diabetics, improves body's immunity. Described polysaccharide is lentinan or Flammukinan, it is possible to improves body immunity, moreover it is possible to blood sugar lowering, blood fat, cholesterol, improves diabetes and arteriosclerosis. Described nanoparticle is nano hydroxyapatite Calx, and nano hydroxyapatite Calx has the advantages such as height targeting, drug controlled release, the dissolution rate of raising insoluble medicine and absorbance as nano-medicament carrier, can improve curative effect of medication and reduce toxic and side effects.
Embodiment 3:
A kind of compound recipe nanometer formulation treating type 2 diabetes mellitus, is mainly grouped into by the one-tenth of following weight portion: aloe acetylated glucomannoglycan 15 parts, cicletanine 6 parts, decanoylacetaldehyde 2 parts, syringaresinol monoglycosides 8 parts, 20 parts of Banana Leaf powder, grapefruit seed extract 7 parts, sodium ethylene diamine tetracetate 4 parts, myristic acid-2.0 parts, syringic acid 0.5 part, gentisic acid 0.3 part, lysine 10 parts, carotenoid 3 parts, antioxidant 0.1 part.
Wherein, the particle diameter of described Banana Leaf powder is 500 ��m, the preparation technology of described Banana Leaf powder is: takes fresh Banana Leaf and cleans, it is placed in immersion treatment 60min in 1.2% sodium bicarbonate solution, pulls out, dry, it is placed in dehydrator inner drying to water content lower than 5%, it is ground into the coarse powder of 40 orders with pulverizer, is crushed to the micropowder of 500 ��m then through super micron mill, namely obtain described Banana Leaf powder. Described grapefruit seed extract is purchased from Xi'an Si Nuote Bioisystech Co., Ltd, and grapefruit seed extract can completely cut off the absorption of fat, postpones the absorption of glucose, reduces body fat, reduces the cholesterol in blood and raises with alleviating blood glucose. Described antioxidant is glutathion, and glutathion possesses anticorrosion, antioxidation, also has the effects such as wide spectrum removing toxic substances, slow down aging, enhancing immunity, antitumor.
The preparation method of a kind of compound recipe nanometer formulation treating type 2 diabetes mellitus, comprises the following steps:
(1) aloe acetylated glucomannoglycan, cicletanine, decanoylacetaldehyde, syringaresinol glucosides, Banana Leaf powder, grapefruit seed extract, sodium ethylene diamine tetracetate, myristic acid, syringic acid, gentisic acid, lysine, carotenoid, antioxidant are weighed by described components by weight percent, standby;
(2) all the components mix homogeneously in mixer above-mentioned steps (1) weighed, adds the filler of 20%, the adhesive of 15%, mixing, makes particle diameter fine grained in 500 micrometer ranges, standby; Described filler is microcrystalline Cellulose, and it does not play ill effect with drug component, and improves pharmaceutical properties. Described adhesive is the alcoholic solution of ethyl cellulose, and in the alcoholic solution of described ethyl cellulose, the mass concentration of ethyl cellulose is 10%, it is simple to granulate.
(3) the fine grained surface obtained by step (2) is mixed pharmaceutically acceptable excipient carry out three layers cladding with protein, polysaccharide, nanoparticle respectively, wherein, ground floor is to be coated with excipient mixture with the protein relative to fine particle mass 1.3 times amount, and the part by weight of protein and excipient is 1:10; The second layer is to be coated with excipient mixture with the polysaccharide relative to fine particle mass 2.8 times amount, and the part by weight of polysaccharide and excipient is 1:10; Third layer is to be coated with excipient mixture with the nanoparticle relative to fine particle mass 5.0 times amount, and the part by weight of nanoparticle and excipient is 1:10. Described excipient is soluble starch, and soluble starch stable in properties with principal agent without incompatibility, does not have side effects, do not affect the treatment. Described protein is soybean protein or trichosanthin, it is possible to provides sufficient nutritional labeling for diabetics, improves body's immunity. Described polysaccharide is lentinan or Flammukinan, it is possible to improves body immunity, moreover it is possible to blood sugar lowering, blood fat, cholesterol, improves diabetes and arteriosclerosis. Described nanoparticle is nano hydroxyapatite Calx, and nano hydroxyapatite Calx has the advantages such as height targeting, drug controlled release, the dissolution rate of raising insoluble medicine and absorbance as nano-medicament carrier, can improve curative effect of medication and reduce toxic and side effects.
The Therapy study of diabetes rat is tested by the nano compound preparation of the present invention:
1, experiment material:
(1) laboratory animal: healthy male Wistar rat 20, diabetic nephropathy male Wistar rat 100, body weight 200-220g, is provided by Zhejiang University's Experimental Animal Center;
(2) Experimental agents: the nano compound preparation that the embodiment of the present invention 1,2,3 prepares, glipizide glipizide tablet (Hainan Zan Bang pharmaceutical Co. Ltd, quasi-word H10930076, the 5mg*30 sheet/bottle of traditional Chinese medicines).
2, experimental technique: 20 healthy male Wistar rats are blank group, by 100 diabetic nephropathy male Wistar rat random packet, it is divided into 5 groups, often group 20, respectively model group, high dose group, middle dosage group, low dose group and glipizide glipizide tablet group. Blank group is fed with normal diet, and other groups are fed with high-energy feed. After one week, each group rat gives corresponding tested material by following dosage gavage: the nano compound preparation that the other gavage embodiment of the present invention 1,2,3 of high, medium and low dosage component prepares is respectively as basic, normal, high dosage, and every rat taking dose is 1.0g/kg; The glipizide glipizide tablet of glipizide glipizide tablet matched group gavage 10mg/kg; Blank group and model group are with isopyknic distilled water gavage.
3, Indexs measure and drawing materials:
(1) body weight: from starting gastric infusion 1d, surveys a body weight in every 10 days.
(2) blood glucose: each group detects each group of rat fasting blood-glucose after feeding 1 week; After gastric infusion surrounding, then detect each group of rat fasting blood-glucose.
(3) blood fat: extract tail blood after 40 days, measure rat blood serum T-CHOL (TC), total triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and HDL-C (HDL-C) content.
4, experimental result data statistics is shown in following table:
The change of table 1-rat blood sugar is compared
Note: compare with blank group, �� P < 0.05, �� �� P < 0.01, compares with model group, �� P < 0.05, �� �� P < 0.01.
The change of table 2-rat body weight is compared
Note: compare with blank group, �� P < 0.05, compares with model group, �� P < 0.05, �� �� P < 0.01.
Table 3-rat is lipids detection results contrast after 40 days
Note: compare with blank group, �� P < 0.05, �� �� P < 0.01, compares with model group, �� P < 0.05, �� �� P < 0.01.
5, conclusion: this experiment judges the compound recipe nanometer formulation of the present invention effect in treatment diabetes by measuring the value of the body weight of diabetes rat, blood glucose and blood fat before and after administration. 1 as shown in Table 1, and the senior middle school's low dose group blood glucose value after administration substantially reduces, and compared with model group, has the difference of significance; Before administration with the model group blood glucose value after administration compared with blank group, all there is extremely significant difference. As shown in Table 2, the body weight of administration Hou40Tian senior middle school low dose group is decreased obviously, and compared with model group, all has the difference of pole significance; By being administered the measured body weight of latter 10 days to 40 days it can be seen that except blank group, the body weight of other group rats all declines to some extent. As shown in Table 3, after administration, the blood fat value of senior middle school's low dose group is decreased obviously, and compared with model group, has the difference of significance; Model group blood fat value compared with blank group, then has extremely significant difference. The blood glucose of glipizide glipizide tablet group, body weight and blood fat and senior middle school's low dose group suitable, but effective not as compound recipe nanometer formulation of the present invention of therapeutic effect. And during nano compound preparation for treating diabetes rat, do not find that rat has any untoward reaction, say, that there is no apparent side effect. Thus, it can be seen that, compound recipe nanometer formulation of the present invention can effectively reduce the blood glucose of diabetes rat, body weight and blood fat, has the curative effect of significance in treatment diabetes, can as the drug use for the treatment of diabetes.
Last it should be noted that, the foregoing is only presently preferred embodiments of the present invention, not in order to limit the present invention, any amendment of making within the principle of the present invention, equivalent replacement, improvement etc., should be included within protection scope of the present invention.

Claims (10)

1. the compound recipe nanometer formulation treating type 2 diabetes mellitus; it is characterized in that, be mainly grouped into by the one-tenth of following weight portion: aloe acetylated glucomannoglycan 8-15 part, cicletanine 3-6 part, decanoylacetaldehyde 1-2 part, syringaresinol monoglycosides 4-8 part, Banana Leaf powder 5-20 part, grapefruit seed extract 3-7 part, sodium ethylene diamine tetracetate 1-4 part, myristic acid 0.8-2.0 part, syringic acid 0.1-0.5 part, gentisic acid 0.1-0.3 part, lysine 3-10 part, carotenoid 1-3 part, antioxidant 0.03-0.1 part.
2. a kind of compound recipe nanometer formulation treating type 2 diabetes mellitus as claimed in claim 1, it is characterised in that the particle diameter of described Banana Leaf powder is 100-500 ��m.
3. a kind of compound recipe nanometer formulation treating type 2 diabetes mellitus as claimed in claim 1, it is characterised in that described antioxidant is glutathion.
4. the preparation method of a kind of compound recipe nanometer formulation treating type 2 diabetes mellitus as described in claim 1-3, it is characterised in that comprise the following steps:
(1) aloe acetylated glucomannoglycan, cicletanine, decanoylacetaldehyde, syringaresinol glucosides, Banana Leaf powder, grapefruit seed extract, sodium ethylene diamine tetracetate, myristic acid, syringic acid, gentisic acid, lysine, carotenoid, antioxidant are weighed by described components by weight percent, standby;
(2) all the components mix homogeneously in mixer above-mentioned steps (1) weighed, adds the adhesive of the filler of 5-20%, 8-15%, mixing, makes particle diameter fine grained in 200-500 micrometer range, standby;
(3) the fine grained surface obtained by step (2) is mixed pharmaceutically acceptable excipient carry out three layers cladding with protein, polysaccharide, nanoparticle respectively, wherein, ground floor is to be coated with excipient mixture with the protein relative to fine particle mass 0.5-1.3 times amount, and the part by weight of protein and excipient is 1:8-10; The second layer is to be coated with excipient mixture with the polysaccharide relative to fine particle mass 1.5-2.8 times amount, and the part by weight of polysaccharide and excipient is 1:6-10; Third layer is to be coated with excipient mixture with the nanoparticle relative to fine particle mass 4.2-5.0 times amount, and the part by weight of nanoparticle and excipient is 1:5-10.
5. the preparation method of a kind of compound recipe nanometer formulation treating type 2 diabetes mellitus as claimed in claim 4, it is characterised in that described excipient is soluble starch.
6. the preparation method of a kind of compound recipe nanometer formulation treating type 2 diabetes mellitus as claimed in claim 4, it is characterised in that described protein is soybean protein or trichosanthin.
7. the preparation method of a kind of compound recipe nanometer formulation treating type 2 diabetes mellitus as claimed in claim 4, it is characterised in that described polysaccharide is lentinan or Flammukinan.
8. the preparation method of a kind of compound recipe nanometer formulation treating type 2 diabetes mellitus as claimed in claim 4, it is characterised in that described nanoparticle is nano hydroxyapatite Calx.
9. the preparation method of a kind of compound recipe nanometer formulation treating type 2 diabetes mellitus as claimed in claim 5, it is characterised in that described filler is microcrystalline Cellulose.
10. the preparation method of a kind of compound recipe nanometer formulation treating type 2 diabetes mellitus as claimed in claim 4, it is characterized in that, described adhesive is the alcoholic solution of ethyl cellulose, and in the alcoholic solution of described ethyl cellulose, the mass concentration of ethyl cellulose is 2-10%.
CN201610051589.7A 2016-01-26 2016-01-26 Compound nanometer preparation for treating diabetes mellitus type 2 and preparation method thereof Pending CN105641674A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610051589.7A CN105641674A (en) 2016-01-26 2016-01-26 Compound nanometer preparation for treating diabetes mellitus type 2 and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610051589.7A CN105641674A (en) 2016-01-26 2016-01-26 Compound nanometer preparation for treating diabetes mellitus type 2 and preparation method thereof

Publications (1)

Publication Number Publication Date
CN105641674A true CN105641674A (en) 2016-06-08

Family

ID=56487177

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610051589.7A Pending CN105641674A (en) 2016-01-26 2016-01-26 Compound nanometer preparation for treating diabetes mellitus type 2 and preparation method thereof

Country Status (1)

Country Link
CN (1) CN105641674A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108968056A (en) * 2018-09-04 2018-12-11 谭建新 A kind of fruit ferment of lower hyperlipidemia, hypertension, hyperglycemia and preparation method thereof
CN115554388A (en) * 2022-11-03 2023-01-03 广州四季泰来生物技术有限公司 Nutrition balance formula for improving female polycystic ovarian hormone level and production process

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050049208A1 (en) * 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and method of preventing diabetes
CN104189285A (en) * 2014-09-12 2014-12-10 广西中医药大学 Traditional Chinese medicine preparation with hypoglycemic effect

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050049208A1 (en) * 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and method of preventing diabetes
CN104189285A (en) * 2014-09-12 2014-12-10 广西中医药大学 Traditional Chinese medicine preparation with hypoglycemic effect

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARKADIY А. SEMENOV等: "Study on the Healing Effect of Syringaresinol β-D-Monoglucoside", 《INTERNATIONAL JOURNAL OF BIOMEDICINE》 *
于红霞等: "《饮食营养与健康》", 28 February 2014, 中国轻工业出版社 *
叶山东等: "《专家解读糖尿病》", 31 January 2015, 安徽科学技术出版社 *
朱法洪: "《生活化学品与健康》", 30 April 2013 *
陆欣玫等: "芦荟乙酰化甘露聚糖的开发与应用", 《第五届芦荟产业发展研讨会论文集》 *
陈广垠: "《降脂就这么简单》", 31 August 2014, 安徽科学技术出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108968056A (en) * 2018-09-04 2018-12-11 谭建新 A kind of fruit ferment of lower hyperlipidemia, hypertension, hyperglycemia and preparation method thereof
CN115554388A (en) * 2022-11-03 2023-01-03 广州四季泰来生物技术有限公司 Nutrition balance formula for improving female polycystic ovarian hormone level and production process

Similar Documents

Publication Publication Date Title
CN107080250A (en) A kind of composition of auxiliary hyperglycemic, beverage and preparation method thereof
US5900240A (en) Herbal compositions and their use as hypoglycemic agents
CN1985851B (en) Lipoid microsphere injection containing toad cake extract and its preparing method
CN101309692A (en) Application of curbitacin or curbitacin combination in leucocyte increasing medicament preparation
CN105641674A (en) Compound nanometer preparation for treating diabetes mellitus type 2 and preparation method thereof
CN102716135B (en) Lupenone prevents in preparation or treats the application in the product of diabetes
CN101744844B (en) Fulvic acid or sodium fulvate substance with hypoglycemic function
CN109125315A (en) Composition and purposes with hypoglycemic, reducing blood lipid and hypotensive activity
Djamil et al. Nanoemulsion of okra fruit extract as antidiabetic treatment
EP3574912B1 (en) Composition for treating diabetic disease
CN107319332A (en) A kind of integration of drinking and medicinal herbs composition with hypoglycemic effect and preparation method thereof
CN107569482B (en) Application of the artemisine compounds in preparation treatment embryonal-cell lipoma drug
US20050048144A1 (en) Herb extract-based cosmeceutical cream for controlling the blood sugar level of diabetes and methods for making it
CN109381455A (en) With the composition for adjusting blood glucose, blood lipid and blood pressure function
EP3978009A1 (en) Traditional chinese medicine increase and decrease prescription for preventing/treating metabolic syndrome and complications thereof
CN104000877A (en) Blood glucose reducing composition and application thereof
WO2018072276A1 (en) Health-care food and preparation method therefor
CN109731019B (en) A composition with chemotherapy synergistic effect comprises components, preparation and application
CN109260205B (en) Application of tetrandrine in preparation of medicine for resisting diabetes and hypertension
CN1294990C (en) Composition of nanometer SOD and ginseng or its extract and its preparation method
CN102836349A (en) Traditional Chinese medicine composition for treating diabetes and preparation method thereof
CN106420697A (en) Polymethoxylated flavone, composition and application of polymethoxylated flavone preparation in preventing or treating diabetes
CN102578451A (en) Health-care food composite capable of decreasing blood sugar
CN108079000A (en) A kind of pharmaceutical composition for treating diabetes and preparation method thereof
CN101181440B (en) Chinese medicine composition for curing hemopathy as well as preparation method and usage thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160608

RJ01 Rejection of invention patent application after publication